Skip to content

礼来

US · LLY #17 按市值排名 上市于 1970
1,257.03 +5.42 +0.43%
实时 - 追踪5344个代码 - 心跳于372秒前 · 2026-10-16 20:01

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了13家。
  • 机构持股总比例基本持平。

机构持股

机构持股比例
79.30% -0.05pp
机构数量
5,307 -13
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund61.63%
Public Company9.49%
Private Company2.88%
Government Pension Fund1.87%
Sovereign Wealth Fund1.37%
Hedge Fund0.92%
Family Office/Trust0.40%
Insurance Company0.26%
Corporate Pension Plan0.20%
Other20.98%

主要股东 截至 2026-06-30

BlackRock 7.58% · 67.54M 股
Vanguard Capital Management, LLC 6.52% · 58.12M 股
The PNC Financial Services Group, Inc. 5.74% · 51.12M 股
Capital Research 4.82% · 42.97M 股
State Street Global Advisors 4.06% · 36.22M 股
FMR 2.91% · 25.97M 股
Other 71.28%
Vanguard Portfolio Management, LLC 2.34% · 20.86M 股
Geode Capital Management, LLC 2.28% · 20.31M 股
T. Rowe Price Group, Inc. 1.57% · 13.96M 股
Norges Bank Investment Management 1.29% · 11.47M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 37次买入 · 13次卖出

姓名职务持股比例
David Ricks Chairperson & CEO 0.09%
Daniel Skovronsky EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology 0.03%
Anne White EVP & President of Lilly Neuroscience 0.01%
Patrik Jonsson EVP, Chief Customer Officer, President of Lilly Diabetes & Obesity and President Lilly USA 0.01%
Anat Hakim General Counsel 0.01%
Edgardo Hernandez EVP & President of Manufacturing Operations 0.01%
Anat Ashkenazi Chief Financial Officer 0.00%
Jacob Van Naarden EVP, CEO of Loxo Oncology & President of Lilly Oncology 0.00%
Ilya Yuffa EVP & President of Lilly International 0.00%
Diogo Rau EVP & Chief Information and Digital Officer 0.00%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-20 Gabrielle Sulzberger Independent Director Other Acquisition +4 $1,164.89
2026-09-20 Jon Erik Fyrwald Independent Director Other Acquisition +8 $1,164.89
2026-09-20 Ralph Alvarez Independent Director Other Acquisition +10 $1,164.89
2026-09-20 Juan Luciano Lead Independent Director Other Acquisition +13 $1,164.89
2026-09-08 Melissa Seymour Executive Vice President of Global Quality Other Disposition -29 --
2026-09-01 Eric Dozier Executive Vice President of Human Resources & Diversity Other Disposition -216 --
2026-09-01 Edgardo Hernandez EVP & President of Manufacturing Operations Other Disposition -13 --
2026-08-16 Gabrielle Sulzberger Independent Director Other Acquisition +4 $1,183.16
2026-08-16 Jon Erik Fyrwald Independent Director Other Acquisition +8 $1,183.16
2026-08-16 Ralph Alvarez Independent Director Other Acquisition +10 $1,183.16
2026-08-16 Juan Luciano Lead Independent Director Other Acquisition +13 $1,183.16
2026-08-16 Patrik Jonsson EVP, Chief Customer Officer, President of Lilly Diabetes & Obesity and President Lilly USA Automatic Disposition -6,500 $1,175.10
2026-08-09 Donald Zakrowski Chief Accounting Officer & VP of Finance Automatic Disposition -2,000 $1,185.01
2026-08-06 Anat Hakim General Counsel Automatic Disposition -5,000 $1,190.00
2026-07-31 Melissa Seymour Executive Vice President of Global Quality Derivative Exercise and Sale -438 $1,148.84
2026-07-31 Melissa Seymour Executive Vice President of Global Quality Derivative Exercise and Retained +542 --
2026-07-19 Gabrielle Sulzberger Independent Director Other Acquisition +4 $1,146.90
2026-07-19 Jon Erik Fyrwald Independent Director Other Acquisition +8 $1,146.90
2026-07-19 Ralph Alvarez Independent Director Other Acquisition +10 $1,146.90
2026-07-19 Juan Luciano Lead Independent Director Other Acquisition +13 $1,146.90

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:01:12 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

礼来 讨论区 1 条评论

  1. the GLP-1 demand curve still doesn’t look like it’s topping, manufacturing capacity is the actual bottleneck here not demand, which is a good problem to have.

    Reply

发表评论